Eagle Asset Management Inc. decreased its stake in Ophthotech Corp. (NASDAQ:OPHT) by 42.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 526,728 shares of the biopharmaceutical company’s stock after selling 391,141 shares during the period. Eagle Asset Management Inc. owned 1.48% of Ophthotech Corp. worth $24,297,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. BlackRock Group LTD raised its stake in shares of Ophthotech Corp. by 53.5% in the first quarter. BlackRock Group LTD now owns 19,687 shares of the biopharmaceutical company’s stock valued at $833,000 after buying an additional 6,858 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Ophthotech Corp. by 20.3% in the first quarter. Renaissance Technologies LLC now owns 362,500 shares of the biopharmaceutical company’s stock valued at $15,323,000 after buying an additional 61,085 shares during the last quarter. Creative Planning raised its stake in shares of Ophthotech Corp. by 61.3% in the second quarter. Creative Planning now owns 5,527 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 2,100 shares during the last quarter. Princeton Capital Management Inc. raised its stake in shares of Ophthotech Corp. by 93.0% in the second quarter. Princeton Capital Management Inc. now owns 18,452 shares of the biopharmaceutical company’s stock valued at $942,000 after buying an additional 8,890 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in shares of Ophthotech Corp. by 26.4% in the second quarter. Alps Advisors Inc. now owns 49,689 shares of the biopharmaceutical company’s stock valued at $2,536,000 after buying an additional 10,373 shares during the last quarter. Institutional investors own 95.80% of the company’s stock.

Institutional Ownership by Quarter for Ophthotech Corp. (NASDAQ:OPHT)

Shares of Ophthotech Corp. (NASDAQ:OPHT) traded down 10.793% on Monday, reaching $34.755. 2,143,671 shares of the company’s stock traded hands. Ophthotech Corp. has a 52-week low of $29.85 and a 52-week high of $80.00. The stock’s market cap is $1.24 billion. The firm’s 50-day moving average is $36.41 and its 200-day moving average is $49.87.

Ophthotech Corp. (NASDAQ:OPHT) last issued its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.64) by $0.07. The company had revenue of $1.67 million for the quarter, compared to the consensus estimate of $6.20 million. Ophthotech Corp. had a negative net margin of 323.19% and a negative return on equity of 916.07%. Analysts anticipate that Ophthotech Corp. will post ($4.94) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Ophthotech Corp. (OPHT) Shares Sold by Eagle Asset Management Inc.” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/28/ophthotech-corp-opht-shares-sold-by-eagle-asset-management-inc.html.

OPHT has been the subject of several research analyst reports. Citigroup Inc. raised their price target on shares of Ophthotech Corp. from $91.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, August 4th. Goldman Sachs Group Inc. reiterated a “sell” rating and issued a $45.00 price objective on shares of Ophthotech Corp. in a research note on Wednesday, August 10th. BTIG Research reiterated a “buy” rating and issued a $92.00 price objective on shares of Ophthotech Corp. in a research note on Friday, August 19th. JPMorgan Chase & Co. lifted their price objective on shares of Ophthotech Corp. from $81.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, September 8th. Finally, Leerink Swann reiterated a “positive” rating and issued a $72.00 price objective on shares of Ophthotech Corp. in a research note on Friday, September 30th. Two equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. Ophthotech Corp. currently has an average rating of “Buy” and an average target price of $87.70.

In related news, President Samir Chandrakant Patel sold 20,000 shares of the stock in a transaction that occurred on Thursday, September 29th. The shares were sold at an average price of $55.17, for a total transaction of $1,103,400.00. Following the transaction, the president now owns 24,239 shares in the company, valued at $1,337,265.63. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David R. Guyer sold 22,060 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $44.37, for a total transaction of $978,802.20. Following the transaction, the chief executive officer now owns 24,541 shares in the company, valued at approximately $1,088,884.17. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Ophthotech Corp. Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.

5 Day Chart for NASDAQ:OPHT

Receive News & Stock Ratings for Ophthotech Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp. and related stocks with our FREE daily email newsletter.